BridgeBio Oncology Therapeutics, Inc. Market Cap ($185.85 Million)
Market Cap & Net Worth: BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. market cap. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) has a market capitalization of $185.85 Million ($185.85 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16599 globally and #3961 in its home market, demonstrating a -12.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BridgeBio Oncology Therapeutics, Inc.'s stock price $2.32 by its total outstanding shares 80107104 (80.11 Million). Also see BridgeBio Oncology Therapeutics, Inc. (BBOT) cash flow conversion for how efficiently the company converts equity into cash flow.
BridgeBio Oncology Therapeutics, Inc. Market Cap History (2025–2026)
BridgeBio Oncology Therapeutics, Inc. market cap history from 2025 to 2026. Data shows growth from $1.00 Billion to $185.85 Million (0.00% CAGR). Check BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price for real-time trading data and today's change.
BridgeBio Oncology Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BridgeBio Oncology Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of BridgeBio Oncology Therapeutics, Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BBOT by Market Capitalization
Companies near BridgeBio Oncology Therapeutics, Inc. in the global market cap rankings as of November 4, 2026. Also see BBOT current and non-current assets for a full breakdown of the balance sheet.
Key companies related to BridgeBio Oncology Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of BridgeBio Oncology Therapeutics, Inc. (2025–2026)
Market capitalization of BridgeBio Oncology Therapeutics, Inc. from 2025 to today. Between 2025 and today, BridgeBio Oncology Therapeutics, Inc.'s market cap moved from $1.00 Billion to $ 185.85 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $185.85 Million | -81.47% |
| 2025 | $1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of BridgeBio Oncology Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $185.85 Million USD |
| MoneyControl | $185.85 Million USD |
| MarketWatch | $185.85 Million USD |
| marketcap.company | $185.85 Million USD |
| Reuters | $185.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more